Facebook      Twitter




IMMUNIZATION NEEDS OF PERSONS Living with HIV: Pediatrics to Geriatrics (17HH03)

Sima S. Toussi, MD, Assistant Professor of Pediatrics; Patricia DeLaMora, MD, Associate Professor of Pediatrics; and Harjot K. Singh, MD, ScM, Assistant Professor of Medicine, Weill Cornell Medical College


Release Date:June 1, 2015
Expiration Date: May 31, 2017
Activity Code: 17HH03

This content is being provided for informational purposes only.

If you have any questions about this process, please email the Center for Continuing and Outreach Education at ccoereg@ca.rutgers.edu or call CCOE Enrollment Services at (800) 227-4852.

As seen in the Summer 2015 edition of



Provided by François-Xavier Bagnoud Center, School of Nursing, Rutgers, The State University of New Jersey and the Center for Continuing and Outreach Education at Rutgers Biomedical and Health Sciences.


This activity is supported by an educational grant from the New Jersey Department of Health (NJDOH)—Division of HIV, STD and TB Services, through an MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS.”

Statement of Need

Over the past 3 years, new recommendations have been made for the primary care immunization of persons living with HIV (PLWH) by the Infectious Diseases Society of America (2013) and the Centers for Disease Control and Prevention (2014). Specific immunization recommendations have been made for children, adolescents, and adults with HIV-infection. These recommendations include: use of the pneumococcal 13-valent protein conjugate vaccine (PCV13) for persons >6 years in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23) with a booster dose of the PPSV23 five years after the initial PPSV23 dose. Because PLWH are at increased risk of pneumococcal pneumonia, it is essential that adequate immunization of PLWH occur and that booster vaccinations are given as recommended in national guidelines.

In addition to pneumococcal vaccinations, influenza vaccinations are recommended annually for persons living with HIV without contraindications ages >6 months. In the United States, influenza results in significant morbidity and mortality which could have been prevented due to vaccination. These recommendations are in addition to those for other FDA approved vaccinations for infants, children, adolescents, and adults.

This activity will assist health care providers with implementation of current recommendations for immunizing persons of all ages living with HIV against preventable diseases.

Target Audience

This activity is designed for physicians, physician assistants, advanced practice nurses, nurses and health educators, and other health care professionals in New Jersey who are involved in the care of people infected with HIV and their non-HIV infected partners.

Method of Participation

Participants should read the learning objectives, review the activity in its entirety, and then complete the self-assessment test, which consists of a series of multiple-choice questions. Upon completing this activity as designed and achieving a passing score of 70% or more on the self-assessment test and submitting a course evaluation, participants will receive a printable credit statement.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Describe recommendations for use of select inactivated and live vaccines for the pediatric to geriatric HIV-infected population
  2. Identify other vaccinations (primary and booster) needed by adolescents and adults living with HIV who have had their primary childhood vaccinations.


Activity Director/CE Academic Advisor

Shobha Swaminathan, MD, Assistant Professor, Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School

Planning Committee

Connie Calisti-Myers, JD, Assistant Commissioner, NJDOH-Division of HIV, STD and TB Services

John Nelson, PhD, CPNP, Program Director, AETC NRC, FXB Center, Rutgers

Andrea Norberg, MS, RN, Executive Director, FXB Center, Rutgers

Michelle Thompson, Program Manager, FXB Center, Rutgers

Elizabeth Ward, MSJ, Executive Director, Rutgers CCOE

Activity Authors

Sima S. Toussi, MD, Assistant Professor of Pediatrics, Weill Cornell Medical College

Patricia DeLaMora, MD, Associate Professor of Pediatrics, Weill Cornell Medical College

Harjot K. Singh, MD, ScM, Assistant Professor of Medicine, Weill Cornell Medical College


Credit is no longer available for this activity.

Peer Review

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, CCOE has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by John Nelson, PhD, CPNP.

Field Test:
This activity was field tested for time required for participation by Noa’a Shimoni, MD, MPH, David Abel, DO, Howard A. Grossman, MD, Anna M. Haywood, MSN, RN, Juanita Howell, MSN, RN, and Laura Bogert, BSN, RN.

Disclosure Disclaimer

In accordance with the disclosure policies of Rutgers University and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/ device not yet approved.

Disclosure Declarations

Harjot Kaur Singh, MD is a member of the Scientific Advisory Board for Gilead Sciences.

Shobha Swaminathan, MD receives grant /research support from Gilead Sciences.

All other authors, planning committee members, peer reviewers and field testers have no relevant financial relationships to disclose.

Off-Label Usage Disclosure

This activity does not contain information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.

Content Disclaimer

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of NJDOH – Division of HIV, STD and TB Services, any manufacturer of pharmaceuticals or devices, or Rutgers University. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.

Copyright © 2015 Rutgers University

All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Rutgers University.

Privacy Policy

To review Rutgers' privacy policy, please see: http://ccoe.rbhs.rutgers.edu/general/privacypolicy.html

Please direct CE related or technical questions to Rutgers at 973-972-4267 or email ccoe@ca.rutgers.edu.


© Copyright 2020, Rutgers, The State University of New Jersey, an equal opportunity, affirmative action institution.

Privacy Policy